Business Context and Reporting Period
This Form 8-K, dated May 28, 2025, reports on e.l.f. Beauty, Inc. (the "Company"). The filing primarily announces the entry into a definitive Merger Agreement to acquire HRBeauty LLC ("rhode") and references the issuance of financial results for the three and twelve months ended March 31, 2025.
Key Financial Metrics and Transaction Terms
The filing details a significant acquisition rather than standard quarterly operating metrics. Key financial terms of the transaction include:
- Total Consideration: Aggregate closing consideration of $800 million, subject to adjustments.
- Payment Structure: $600 million in cash and approximately $200 million in Company common stock.
- Stock Valuation: Stock consideration valued at $77.1685 per share based on a 10-day VWAP.
- Contingent Consideration (Earn-Out): Up to $200 million in additional cash based on rhode's revenue performance over three years post-closing ($100 million for meeting targets and up to $100 million for overachievement).
- Financing: The Company expects to fund a portion of the cash consideration through debt financing, with commitment letters secured concurrently with the agreement.
- Termination Fee: A reverse termination fee of $65 million payable by the Company under specific circumstances.
Note: Specific revenue, profit, cash flow, and margin figures for the period ended March 31, 2025, are referenced as being contained in a press release (Exhibit 99.2) but are not explicitly detailed in the text of this filing.
Material Changes and Transaction Timeline
The primary material change is the strategic acquisition of rhode. The transaction is expected to close during the Company's second quarter of fiscal year 2026 (ending September 30, 2025). Upon closing, rhode will become a wholly owned subsidiary of e.l.f. Cosmetics, Inc. The deal is not subject to a financing condition but requires customary regulatory approvals, including the expiration of the HSR Act waiting period.
Guidance, Risks, and Contingencies
Management Commentary and Outlook: The Company intends to integrate rhode to realize anticipated benefits of combined operations. The transaction is subject to customary closing conditions, including regulatory approvals, absence of legal impediments, and the accuracy of representations and warranties.
Risks and Contingencies:
- Regulatory Risk: Failure to obtain required regulatory approvals in a timely manner.
- Financing Risk: Failure to obtain debt financing arrangements, though the agreement is not subject to a financing condition.
- Integration Risk: Risks associated with integrating the acquired business and retaining key personnel.
- Termination Risk: The agreement may be terminated if the Merger is not consummated by September 25, 2025, or if a material adverse effect occurs.
- Insurance: The Company will obtain a $100 million representations and warranties insurance policy as its sole remedy for breaches (excluding fraud).
Investor Verification Checklist
- Verify the specific revenue and profit figures for the quarter ended March 31, 2025, in the attached press release (Exhibit 99.2).
- Confirm the status of regulatory approvals, specifically the Hart-Scott Rodino (HSR) waiting period.
- Review the terms of the debt financing commitment letters to assess leverage impact.
- Monitor the timeline for the expected closing in Q2 FY2026 (ending September 30, 2025).
- Assess the potential dilution impact of issuing approximately $200 million in stock consideration.